Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial

OBJECTIVE: To evaluate whether the addition of colchicine to standard treatment for COVID-19 results in better outcomes. DESIGN: We present the results of a randomised, double-blinded, placebo-controlled clinical trial of colchicine for the treatment of moderate to severe COVID-19, with 75 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopes, Maria Isabel, Bonjorno, Leticia P, Giannini, Marcela C, Amaral, Natalia B, Menezes, Pamella Indira, Dib, Saulo Musse, Gigante, Samara Libich, Benatti, Maira N, Rezek, Uebe C, Emrich-Filho, Laerte L, Sousa, Betania A A, Almeida, Sergio C L, Luppino Assad, Rodrigo, Veras, Flavio P, Schneider, Ayda, Rodrigues, Tamara S, Leiria, Luiz O S, Cunha, Larissa D, Alves-Filho, Jose C, Cunha, Thiago M, Arruda, Eurico, Miranda, Carlos H, Pazin-Filho, Antonio, Auxiliadora-Martins, Maria, Borges, Marcos C, Fonseca, Benedito A L, Bollela, Valdes R, Del-Ben, Cristina M, Cunha, Fernando Q, Zamboni, Dario S, Santana, Rodrigo C, Vilar, Fernando C, Louzada-Junior, Paulo, Oliveira, Rene D R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Infections
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868202/
https://www.ncbi.nlm.nih.gov/pubmed/33542047
http://dx.doi.org/10.1136/rmdopen-2020-001455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868202/
https://www.ncbi.nlm.nih.gov/pubmed/33542047
http://dx.doi.org/10.1136/rmdopen-2020-001455

Ejemplares similares